<sub id="dccn5"></sub><strike id="dccn5"><sup id="dccn5"><mark id="dccn5"></mark></sup></strike>
  1. <wbr id="dccn5"><legend id="dccn5"></legend></wbr>

    <nav id="dccn5"></nav>

  2. Regeneron Perspectives

    Regeneron Perspectives

    An ongoing series of thought-provoking articles on issues of the day from Regeneron’s leaders.

    POINEERS IN ANTIBODY MEDICINE

    Discover how Regeneron has broken down communication walls between preclinical and clinical researchers to orchestrate optimal strategies for getting a drug from bench to bedside.

    TAPPING PRECLINICAL UNDERSTANDING FOR SMARTER TRIALS

    The story behind Regeneron's first Costimulatory Bispecific Clinical Trial

    ADDRESSING PAINFUL MEMORIES FROM WITHIN

    Discover how Regeneron scientists are tapping into their long-standing expertise in growth factor biology to better understand their potential for treating chronic pain. Learn more.

    SEEING A NEW WAY FOR DIABETIC RETINOPATHY

    Regeneron scientists discuss their motivations for studying diabetic retinopathy (DR) and how their job was to not only establish a new treatment approach, but also shifting the mindset around the disease.

    LISTENING & LEARNING FROM THE RARE DISEASE COMMUNITY

    Regeneron listens and learns from those who live with rare diseases to help bring meaningful change where there are frequently few or no treatments. Learn more.

    JUMPING ACROSS THE POND WITH SUCCESS

    Niall O'Leary, Site Head of Industrial Operations and Product Supply in Ireland, shares his story of how he helped to take an American company and make it work in Ireland by embodying shared values.

    MAKING INNOVATION MATTER FOR PATIENTS

    David Weinreich, head of Global Clinical Development, discusses the value of thoughtful innovation in biotech and how Regeneron works to put patients first.

    YOU COULD CALL US CORPORATE RESPONSIBILITY TRENDSETTERS

    Hala Mirza, SVP of Corporate Communications and Citizenship at Regeneron, discusses corporate responsibility and explains Regeneron's own responsibility strategy. Read more.

    THE HEROES AND PROBLEM SOLVERS OF TOMORROW

    Our President & CSO, George Yancopoulos, discusses why we must recognize the next generation of scientists as heroes, and how we can support their efforts.

    STACKING THE DECK FOR GENETIC DISCOVERY

    Regeneron is speeding up novel gene discovery by working with founder populations such as the Amish community. This makes it possible for scientists to identify genetic anomalies with a much smaller sample size. Learn more.

    LOOKING FORWARD WITH HOPE

    The global community faces several questions about disease, food security, and climate change to name a few. How do we overcome these? One way is to support the Regeneron Science Talent Search. These passionate, skilled young people bring fresh perspectives to significant global problems.

    THE REAL HEALTHCARE PROBLEM IS BIGGER THAN YOU THINK

    As physician-scientists and biotech leaders, we have grown increasingly concerned about the current dialogue on the biopharma industry, which tends to focus on short-term issues. But, we fear there are even more important longer-term issues at stake...

    MAKING A DRUG YOU HOPE NO ONE WILL EVER NEED

    Regeneron’s head of Research & Development, Neil Stahl, discusses why we are researching treatments we hope no one will ever need. By harnessing the power of our technology, we are working on medicines to treat infectious diseases like Ebola.

    WHEN THE STUDENT IS A COMPUTER: TEACHING MACHINES TO DO NEW TRICKS

    How do you spark a scientific revolution in genomics? Pair lightning-fast, computational pattern recognition with an unprecedented amount of health data. The Regeneron Genetics Center® is leveraging the power of artificial intelligence and machine learning to mine robust genetic and real-world heath data.

    草莓视频